Barrett Elizabeth A. 4

What Happened

• Elizabeth A. Barrett, a director of Allogene Therapeutics (ALLO), was granted 95,400 restricted stock units (RSUs) on 2026-06-18. The RSUs were awarded at $0.00 (no cash paid) and are recorded as a derivative award (code A) — total immediate cash value reported = $0.00. Each RSU represents a contingent right to one share of common stock upon vesting.

Key Details

• Transaction date and price: 2026-06-18; grant price $0.00 per RSU (award).
• Quantity: 95,400 RSUs granted.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting and deferral (footnote): RSUs vest in two equal semi-annual installments over the one‑year period from the grant date. The reporting person elected to defer receipt of shares upon vesting under the company’s Non‑Employee Director Compensation Policy until the earlier of (i) 30 days after separation from service or (ii) a change in control.
• Filing timeliness: Form 4 was filed 2026-06-23 for a 2026-06-18 transaction (appears to be filed after the standard 2-business‑day reporting window).

Context

• RSU grants are a common form of director compensation and are treated as derivative awards until they vest into actual shares; they are not an open‑market purchase or sale. Such awards do not necessarily signal immediate buying or selling intent by the insider. The deferral election means shares may not be delivered to the director at vesting and could be delayed until separation or a change in control.